key: cord-0777718-bgppzq9o
authors: Flacco, Maria Elena; Acuti Martellucci, Cecilia; Bravi, Francesca; Parruti, Giustino; Mascitelli, Alfonso; Mantovani, Lorenzo; Boccia, Stefania; Manzoli, Lamberto
title: SARS-CoV-2 lethality did not change over time in two Italian Provinces
date: 2020-11-12
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofaa556
sha: 65461fb16112cddf6cfe83af59d8621dcc15fd64
doc_id: 777718
cord_uid: bgppzq9o

This retrospective cohort study included all the subjects diagnosed with SARS-CoV-2 infection (n=2493) in two Italian Provinces. 258 persons deceased, after a median of 14.0±11.0 days. Adjusting for age, gender, and main comorbidities, the ≥28-day case-fatality rate did not decrease from March to April, 2020 (adjusted HR 0.93; p=0.6).

As of mid-July, 2020, SARS-CoV-2 pandemic has caused more than 500,000 deaths worldwide 1 , with largely discrepant case-fatality rates across countries (from <1% to 16%) 2 , likely due to differences in population age structure 3, 4 , variations in testing policies and case recording 5 , and/or preparedness of the healthcare system, which in turn is affected by the intensity of the spread 4, 5 .

Since the start of the pandemic, Italy has been among the countries with the highest death toll, with nearly 35,000 recorded deaths 1 , and an estimated case-fatality rate of 14% 2 , which peaked at 20% among the citizens aged ≥80 years 6 .

In the last months, it has been suggested that SARS-CoV-2 lethality may have decreased, mostly as a consequence of more tailored therapeutic approaches [7] [8] [9] [10] [11] . Although the claims were made by physicians actively engaged in the care of infected patients, the available evidence is anecdotal or based upon case-studies.

We analysed the data of all infected cases in two Italian Provinces to evaluate whether SARS-CoV-2 case-fatality rate decreased with time, adjusting for main potential confounders.

Provinces of Ferrara and Pescara, between March 3 (the onset date of the first cases), and May 3, 2020. All participants were followed up to May 31, 2020. All infections were diagnosed by the central laboratories of Ferrara University Hospital or Pescara Hospital through RT-PCR (Reverse transcription polymerase chain reaction) test on nasopharyngeal swabs, and were confirmed by the Italian National Institute of Health. Information on age, gender, and comorbidities were collected from local registries, clinical charts (for hospitalized patients), and through data-linkage with hospital A c c e p t e d M a n u s c r i p t 5 discharge abstracts. To gather further information on prior clinical history of the included subjects, the above records were further linked (through anonymized unique patient identifiers) with drug prescription datasets, which include all medicines prescribed by the Italian Health Service and dispensed by both community and hospital pharmacies (known as "Ministry Records D and F").

Electronic databases were queried from the day of the diagnosis until January 1st, 2015. All data have been revised manually by two physicians (LM-MEF), and the following conditions have been included in the analyses: hypertension, type II diabetes, major cardiovascular diseases (heart failure, myocardial infarction and stroke -CVD), chronic obstructive pulmonary diseases (COPD, bronchitis, pneumonia, asthma, and emphysema), cancers and renal disease. No additional data were collected.

The study complies with the Declaration of Helsinki; the research protocol was approved by the Ethics Committee of the Emilia-Romagna Region (code 287, approved on March 24, 2020), and the requirement for informed consent was waived because of the retrospective and pseudo-anonymized nature of the data.

We compared the case-fatality rate (fatal/confirmed cases) during the first 29 days after index day (from March 3 to March 31) with that of the second half of the period (days 30-63; from April 1 to May 3). For the sake of simplicity, the second period, composed by April and a few days of May, will be defined as "April". The differences between the two periods were initially evaluated using t-test for continuous variables, and chi-squared test for categorical ones. The potential independent predictors of death were then evaluated using Cox proportional hazards analysis (censoring at May 31, to include ≥28 days of follow-up). The hazard ratio (HR) predicting the risk of death in April vs

March was computed twice, either without and with an incorporated frailty term, in order to account for cluster-specific random-effects potentially arising from the inclusion of cases diagnosed A c c e p t e d M a n u s c r i p t 6 in two different Provinces. All covariates were included a priori in the model in their original form, with the exception of age, which was treated as either continuous or ordinal, to explore several age classes. Schoenfeld's test was used to assess the validity of proportional hazards assumption, and Nelson-Aalen cumulative hazard estimates to check the validity of constant incidence ratios during follow-up 12 . Censoring at 28 days of follow-up, a random-effect logistic regression was also fit, with province as the cluster unit. The same above criteria were used to build the final model. Missing data were <5% in all primary analyses; therefore no missing imputation technique was adopted.

Statistical significance was defined as a two-sided p-value<0.05, and all analyses were carried out using Stata, version 13.1 (Stata Corp., TX, 2014). The same analytical approach was adopted to assess a previous dataset 13 , which was based upon samples collected up to April 25, using a shorter, 10-days follow-up period.

The sample consisted of 2493 subjects (mean age 58.6y±21.1; 47.7% males); of them, 33.0% were hypertensive, 13.0% diabetics, and 15.5% with CVD; a total of 914 subjects (36.7%) required hospital assistance. Some of the characteristics of the sample significantly varied from March to April. Infected subjects were older by 3.1 years, and the proportion of females, diabetics, subjects with CVD, cancer and renal diseases significantly increased (Table 1) c c e p t e d M a n u s c r i p t 7 than 60 years. In April, six deaths occurred in subjects younger than 70 years (two among those younger than 60y). Table 2 , in the overall sample the crude SARS-CoV-2 lethality significantly increased from March to April (from 9.5% to 12.1%; p=0.042). The increase was significant among the males (from 9.9% to 15.8%; p=0.005), and those without hypertension (from 4.4% to 6.7%; p=0.040), diabetes (from 7.4% to 10.7%; p=0.005), COPD (from 8.5% to 11.1%; p=0.040) and cancer (from 8.7% to 11.3%; p=0.050). No significant change were observed among the other categories of subjects.

Multivariate Cox analysis did not confirm univariate results: adjusting for age, gender, hypertension, diabetes, CVD, COPD, cancer and renal disease, the HR of death of those diagnosed in April, as compared to March, was no more significant: 0.93 (95% Confidence Interval -CI: 0.71-1.21 - Table   2 ), and did not change either including or excluding from the analyses the Province of diagnosis.

From March to April, the risk of death did not significantly change in any subset of the sample, with the only exceptions of the females (adjusted HR: 0.65; 95% CI: 0.44-0.95) and diabetics (0.57; 0.34-0.94), whose risk significantly decreased ( Table 2 ). The results of the random-effect logistic regression did not vary: overall, the adjusted odds ratio of death at 28 days was 0.77 (95% CI: 0.55-1.07; p=0.12) for those diagnosed in April, as compared to the subjects detected in March.

In this sample from two Italian Provinces, after adjusting for several potential confounders, SARS-CoV-2 case-fatality rate did not significantly decrease from March to April 2020, overall and in any age-class. The mortality trend throughout time was stable across all categories of risk, with the only exceptions of females and diabetics, both showing a significantly lower death rate in April, as compared to March. Therefore, our data do not support the hypothesis of a decline in SARS-CoV-2 lethality, which has been first suggested by some clinicians 7-11 , following a reduction in the number of severe cases requiring hospitalization or ICU support 14 It is worth considering, indeed, that none of the potential explanations to support a decline in virus lethality have been demonstrated so far 18 : less virulent virus strains have not been reported 9 ; none of the treatments that have been gradually administered to the study participants during the course of the pandemic (including antivirals, low molecular weight heparin and monoclonal antibodies against inflammatory cytokines) has been proven effective to date 19 20 ; finally the healthcare system in the two Provinces under study has never been overcrowded during the pandemic 21 .

The present data are updating a previous, preliminary analysis 13 , significantly expanding the sample and length of follow-up. Yet, they require confirmation from larger datasets across multiple countries, comparing more distant time frames (as one month might be too short to detect substantial changes in health-care system preparedness and medical treatments), and accounting for additional potential confounders (such as body mass index -which we initially did not include among the variables to collect, but later emerged as a significant predictor of death from COVID-19 22 ,23 -or data regarding acute physiology, organ damage or vital signs observed among hospitalized subjects 24 ), during time periods with a stable diagnostic capacity. In fact, in both the selected regions the number of RT-PCR tests increased substantially from March to April (from a total of A c c e p t e d M a n u s c r i p t 9 500/daily to almost 6000/daily) 25, 26 , and it cannot be excluded that the proportions of undetected infections or unrecognized COVID-19 deaths were unbalanced over time. It should be noted, however, that in the Regions under examination the positivity rate slightly declined throughout the time frame 26 , which may likely reflect a consistent increase in the diagnostic capacity, in spite of the rise in the number of positive cases.

Another limitation of the present study is the lack of specific information on the treatments against COVID-19 administered in hospital or prescribed at home. It is possible, or even likely, that the medical approach varied between March and April, potentially impacting lethality. However, there still are scarce evidences of effectiveness for most of the treatments that were used in the selected periods (lopinavir/ritonavir, hydroxychloroquine, and tocilizumab) 19 20 . Also, and importantly, the evaluation of the potential motivations of the observed trend over time (including the impact of each risk factor or adopted treatment) was beyond the scope of the study, whose main aim was to describe whether a change in SARS-CoV-2 lethality occurred over time, regardless of any treatment, patient characteristic, of healthcare services change.

Male gender and some comorbidities were more frequent among the subjects infected in April, which may have increased the observed lethality. However, the CFRs remained similar between March and April even when the sample was stratified for the presence of comorbidity, and these results were confirmed in multivariate analyses. It is worth noting that we relied on routinely collected hospitalization data to define comorbidities for non-hospitalized subjects (63.3% of the sample). Although this source of information may underestimate the prevalence of those comorbidities that rarely lead to hospitalization (such as mild COPD, hypertension or diabetes), we integrated these data (retrospectively collected up to 8 years before) with drugs prescriptions, which typically limit the inadequacy of disease burden estimates 17 . Indeed, collecting information on the clinical history registered before the epidemic onset may increase the accuracy of the data, as the experience with the early days of the pandemic suggests that the reliability of clinical history was A c c e p t e d M a n u s c r i p t 10 limited, mainly due to critical patient conditions, common distance of relatives who could not confirm prior conditions, or lack of time to spend on clinical history taking due to the overwhelming number of observed cases 17 .

Acknowledging these caveats, our data provide the most comprehensive evidence of a lack of a significant decrease of SARS-CoV-2 case-fatality rate between March and April, 2020, on a prospective sample, adjusting for several potential predictors of death. We trust that some of the many ongoing trials testing new therapies 27,28 -starting from those reporting promising results on dexamethasone 29 -will determine a breakthrough in the clinical course of the pandemic. The HR predicting the risk of death in April vs March was computed twice, adopting two separate models: in the first (*) a Cox proportional hazard analysis was performed; in the second (**), a frailty term was incorporated to the Cox model, in order to include cluster-specific random-effects potentially arising from the presence of patients diagnosed in two different Provinces.

COVID-19 Coronavirus Outbreak. Dadax

Demographic science aids in understanding the spread and fatality rates of COVID-19

What Other Countries Can Learn From Italy During the COVID-19 Pandemic

Covid-19: A Dynamic Analysis of Fatality Risk in Italy

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Estimation of risk factors for COVID-19 mortalitypreliminary results

Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis

On the Origin and Continuing Evolution of SARS-CoV-2

Off-label Use of Tocilizumab in Patients with SARS-CoV-2 Infection

LMWH in adult COVID-19 patients [Eparine a basso peso molecolare nei pazienti adulti con COVID-19

Multicentric cohort study on the long-term efficacy and safety of electronic cigarettes: study design and methodology

SARS-CoV-2 lethality decreased over 1 time in two Italian Provinces

Italian Institute of Health. COVID-19 integrated surveillance: key national data. Italian Institute of Health

Lower nasopharyngeal viral load during the latest phase of COVID-19 pandemic in a Northern Italy University Hospital

COVID-19 Italia -Monitoraggio della situazione

Characteristics and outcomes of a cohort of COVID-19 patients in the Province of Reggio Emilia

No evidence for distinct types in the evolution of SARS-CoV-2

Potential Antiviral Drugs Under Evaluation for the Treatment of COVID-19. NIH

Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review

Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations

How important is obesity as a risk factor for respiratory failure, intensive care admission and death in hospitalised COVID-19 patients? Results from a single Italian centre

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Gedi Visual

Lab24 Il Sole 24 Ore -Coronavirus in Italia, i dati e la mappa

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t